Clopidogrel binds to lp-pla2 and inhibits the enzyme activity. A new pleiotropic effect of this antiplatelet drug? M.E. Tsoumani, C.C. Tellis, M.V. Chatziathanasiadou, A.N. Katsikoudi, V.G. Kontogianni, A.G. Tzakos, A.D. Tselepis
SGLT2 inhibitors: what to expect in the future Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf
The use of dapagliflozin in the treatment of type 2 diabetes mellitus Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf
Non-alcoholic fatty liver disease in HIV-infected patients without viral hepatitis. What can we do about their cardiovascular risk? Georgios Sfikas, Chrysoula Boutari, Konstandinos Tassios, Konstantinos Kaitanidis, Eydoxia Mitsiou, Vasilios G. Athyros
Metabolic syndrome, Barrett’s oesophagus, the risk of oesophageal adenocarcinoma, and statin treatment Chrysoula Boutari, Stella-Maria Angelopoulou, Georgios Sfikas, Konstantinos Kaitanidis, Konstantinos Tziomalos, Vasilios G. Athyros
Intensive glucose control in patients with type 2 diabetes mellitus and incidence of cardiovascular events. Has this issue been resolved? K. Kaitanidis, C. Boutari, A. Lazaridis, M. Doumas, K. Tziomalos, V.G. Athyros
Levels of Platelet Activating Factor and its metabolic enzymes in HIV-infected, naive male patients V.D. Papakonstantinou, M. Chini, G.M. Stamatakis, N. Mangafas, N. Tsogas, E. Fragopoulou, P. Gargalianos, S. Antonopoulou, C.A Demopoulos, M-C Lazanas
Effects of monotherapy with high-dose rosuvastatin compared with the combination of low-dose rosuvastatin with fenofibrate or n-3 fatty acids on non-lipid serum parameters in patients with severe mixed dyslipidemia AP. Agouridis, TD. Filippatos, MS. Kostapanos, V. Tsimihodimos, DP. Mikhailidis, AD. Tselepis, MS. Elisaf